(310) 476-7002
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
On February 28, 2014, MMRGlobal, Inc., through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, the
"Company"), and Walgreen Co. ("Walgreens") entered into a Settlement and Licensing Agreement (the
"Agreement") to resolve two patent infringement lawsuits brought by the Company.
Pursuant to the terms of the Agreement, Walgreens purchased a Non-Exclusive License to the Company's family of patents. The
settlement arises from litigation involving the Company's U.S. Patent No. 8,301,466 and U.S. Patent No. 8,498,883.
Pursuant to the terms of the Agreement, Walgreens has also agreed to sell the Company's MyMedicalRecords Personal Health Record (the
"MMR-PHR") on drugstore.com.
In addition to the above terms, the Agreement contains customary provisions, including the term of the Agreement, representations,
warranties, indemnities and confidentiality by each of the Company and Walgreens. The Company and Walgreens have also agreed to dismiss the
lawsuits and other proceedings filed against each other.
The above summary does not purport to be a complete description of the terms of the Agreement and is qualified in its entirety by
reference to the Agreement, which the Company will file as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending
March 31, 2014. Portions of the Agreement may be omitted in accordance with a request for confidential treatment that the Company expects
to submit to the U.S. Securities and Exchange Commission.
In addition, a copy of the press release announcing on March 6, 2014 the Agreement is attached hereto as Exhibit 99.1 and is hereby
incorporated by this reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit
Number |
|
Description |
99.1 |
|
Press Release dated March 6, 2014.
|
|
|
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MMRGLOBAL, INC.
|
March 6, 2014 |
|
By: /s/ Robert H. Lorsch
Robert H. Lorsch
Chief Executive Officer
|
EXHIBIT INDEX